Top Suppliers:I want be here


141505-33-1

141505-33-1 structure
141505-33-1 structure
  • Name: Levosimendan
  • Chemical Name: levosimendan
  • CAS Number: 141505-33-1
  • Molecular Formula: C14H12N6O
  • Molecular Weight: 280.285
  • Catalog: API Circulatory system medication Anti-congestive heart failure medicine
  • Create Date: 2018-06-15 12:11:54
  • Modify Date: 2024-01-02 12:09:32
  • Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3].

Name levosimendan
Synonyms Levosimedan
Mesoxalonitrile (-)-[p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl]phenyl}hydrazono)malononitrile
(R)-[[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile
Propanedinitrile, 2-[2-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-
Levosimendan
(R)-(-)-2-[4-(4-methyl-6-oxo-1,4,5,6,-tetrahydropyridazin-3-yl)phenylhydrazono]propanedinitrile
MFCD00867135
Simdax
(2-{4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazinyliden)propandinitril
2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
(R)-Simendan
Description Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3].
Related Catalog
References

[1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245.

[2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7.

[3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.

Density 1.3±0.1 g/cm3
Melting Point 216-219ºC (dec.)
Molecular Formula C14H12N6O
Molecular Weight 280.285
Exact Mass 280.107269
PSA 113.43000
LogP 0.59
Index of Refraction 1.673
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302-H312-H332
Precautionary Statements P280
Hazard Codes Xn
Risk Phrases R20/21/22
Safety Phrases S36/S37
RIDADR NONH for all modes of transport
RTECS TY1570210

~%

141505-33-1 structure

141505-33-1

Literature: WO2011/7123 A1, ; Page/Page column 11-12 ;

~%

141505-33-1 structure

141505-33-1

Literature: WO2011/7123 A1, ;

~%

141505-33-1 structure

141505-33-1

Literature: WO2011/7123 A1, ;

~%

141505-33-1 structure

141505-33-1

Literature: WO2011/7123 A1, ;
Precursor  4

DownStream  0